Cancer Archives

News and Trends 6 Apr 2022

Immunocore Approvals Open Door for TCR Cancer Drugs

The EU has followed the FDA in granting market approval to Kimmtrak, the first-ever bispecific drug based on a cancer-hunting protein called a T-cell receptor (TCR). These regulatory wins by the UK firm Immunocore pave the way for other treatments deploying TCRs. TCRs have become a hot topic in immuno-oncology. Many companies are developing cancer […]

April 6, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 31 Mar 2022

Precision Medicine Startups Increase Focus on Data Access and Privacy

Low-cost genetic sequencing is becoming increasingly accessible and profitable for companies, but data protection and ownership remains a key issue for many individuals. Sano Genetics is one of many firms driving precision medicine by creating a more mutually beneficial relationship between patients and pharma companies. The falling costs of DNA sequencing are leading to serious […]

March 31, 2022 - 4 minutesmins - By Anita Chakraverty

radiopharmaceutical treatments precirix jeito

News and Trends 17 Mar 2022

€80M Series B Establishes European Champion in Radiopharmaceuticals

Big European venture capital firms Jeito, Forbion, and Inkef Capital have teamed up to propel the local radiopharmaceutical scene by investing €80M in the Belgian firm Precirix. Europe has a long history of expertise in the development of radiopharmaceutical drugs. One of the pioneers in the field was Advanced Accelerator Applications (AAA) in France. AAA […]

March 17, 2022 - 4 minutesmins - By Jonathan Smith

CAR-T cell therapy, cancer therapy, cell therapy

Combination Therapies: Opportunities for Improved CAR-T Cell Therapy?

Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However, CAR-T therapy still faces limitations. How can combination therapy enhance its success in treating cancer? Combination therapy involves pairing two cancer treatments with each other to enhance the benefits of both. CAR-T cell therapy, which uses white blood cells called […]

March 10, 2022 - 6 minutesmins - By Alexander Burik

norway cytovation cancer immuno oncology

News and Trends 26 Jan 2022

Norwegian Biotech Put on the Map with €18M Oncology Round

The immuno-oncology startup Cytovation has raised €17.7M (NOK 180M) in one of Norway’s biggest Series A rounds in life sciences. Historically, Norway’s biotech scene has not seen the kind of venture capital funding characteristic of health and biotech in the UK and US. However, Norwegian biotech is growing and has seen more successes than many […]

January 26, 2022 - 3 minutesmins - By Dan Samorodnitsky

spatial transcriptomics, DNA, DNA double-helix, digital information

How is Spatial Transcriptomics Changing the Immuno-Oncology Field?

The advent of next-generation sequencing has led to the rise of novel gene expression profiling methods like spatial transcriptomics. How will this revolutionary approach, powered by high-quality multi-omics biospecimen, impact personalized immuno-oncology therapy in the future? Next-generation sequencing (NGS) technologies have revolutionized the way scientific research is conducted, triggering new research paradigms and providing novel […]

November 23, 2021 - 7 minutesmins - By Sudha Sundaram

News and Trends 22 Oct 2021

Gene-Edited T Cell Therapy Players Battle Safety Doubts

Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial. Industry experts see these events as a reality check for the nascent field. Off-the-shelf treatments that use genetically engineered T cells to treat diseases suffered […]

October 22, 2021 - 5 minutesmins - By Anita Chakraverty

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […]

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Aug 2021

Artios’ €129M Series C Pushes Limits of DNA Repair in Cancer

The UK firm Artios Pharma raised a huge Series C round last week in one of many efforts to develop cancer drugs that target the DNA repair systems of our cells. Artios Pharma bagged €129M (£110M) last week in a venture capital round led by the US-based firms Omega Funds and TCG X. The proceeds […]

August 6, 2021 - 4 minutesmins - By Anita Chakraverty

News and Trends 28 Jul 2021

Microbiome Medicines Could Power Up CAR-T Cell Therapies

The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may help CAR-T cell therapies penetrate and kill solid tumors. A recent study conducted by researchers at Philipps-University Marburg, University Hospital Würzburg, and the Leeds-based company 4D Pharma showed that metabolites produced by the gut bacteria […]

July 28, 2021 - 5 minutesmins - By Mark Zipkin

News and Trends 8 Jul 2021

The Top European Biotech Funding Rounds in June

While oncology and psychedelics dominated European biotech’s biggest funding rounds last month, startup seed financing focused more on gene therapy and drug discovery. Last month saw some momentous events for Europe’s biotech heavyweights. GSK paid an impressive €524M ($625M) upfront to co-develop an immuno-oncology candidate with iTeos Therapeutics in Belgium. Meanwhile, the German antibody drug […]

July 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […]

June 30, 2021 - 5 minutesmins - By Victor Kotsev

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us